Checkpoint Therapeutics, Inc. (CKPT) - Multiplikator Forward P/S
Checkpoint Therapeutics is implementing robotic systems and AI to accelerate the discovery of immuno-oncology agents. The projected P/S ratio reflects the current market valuation, with the metric standing at 9239.00. Digital data analysis enables the company to efficiently manage global research. The market share capture strategy is based on discount pricing for the drug following FDA approval.
Rincian metrik keuangan lan pasar Checkpoint Therapeutics Inc (CKPT)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Utang marang Ekuitas Checkpoint Therapeutics|CKPT - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Checkpoint Therapeutics|CKPT - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Checkpoint Therapeutics Inc|CKPT - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Checkpoint Therapeutics|Indikator likuiditas cepet checkpointtx.com
- rincian asil keuangan lan kelipatan valuasi:
CKPT - Bathi sawise mbayar pajeg|Bathi mangsa ngarep Checkpoint Therapeutics|CKPT - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Checkpoint Therapeutics, Inc|CKPT - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Checkpoint Therapeutics Inc|CKPT - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Checkpoint Therapeutics|CKPT - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan checkpointtx.com|CKPT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Checkpoint Therapeutics
- data dodolan lan asil:
Analisis wiwitan perusahaan:Checkpoint Therapeutics, Inc. CKPT
The forward P/S reflects the ratio of current market capitalization to expected revenue, capturing the trend of market expectations regarding business value per unit of sales. By analyzing the forward P/S chart for Checkpoint Therapeutics (CKPT), an investor assesses the justification for the premium over assets, considering the strategy of aggressive oncology market capture through price dumping as the drug enters the commercialization stage following FDA approval.
Analisis perusahaan pesaing
Multiplikator Forward P/S ONC (BeiGene)|Rega forward marang dodolan HALO|RevMed - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ascentage Pharma Corp|CGON: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan urogen.com|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Multiplikator Forward P/S Personalis Inc|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|DCTH: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|aurabiosciences.com (AURA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Candel - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Accuray Inc ARAY|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ACTU|Multiplikator forward rega marang pendapatan CTOR|HURA (TuHURA) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Rega forward marang dodolan|Aadi Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan XBIT (XBiotech Inc.)|CVM: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OS Therapies Inc. (OSTX)|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|ARTV: Rega forward marang dodolan|Multiplikator Forward P/S ANL|Multiplikator Forward P/S verupharma.com (VERU)|Rasio rega marang prakiraan pendapatan Tempest Therapeutics, Inc. TPST|XLO (Xilio Therapeutics Inc) - Rega mangsa ngarep marang pendapatan|Enochian BioSciences - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Mural Oncology plc|KAPA (kairospharma.com) - Multiplikator forward rega marang pendapatan|OnKure Therapeutics (OKUR) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan GDTC|CRIS (Curis Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S APLM|Rasio kapitalisasi marang dodolan sing dikarepake Tharimmune Corporation|Multiplikator Forward P/S ADVB (Advanced Biomed)|GNPX - Multiplikator forward rega marang pendapatan|CLDI - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Sunshine Biopharma Inc. SBFM|XBIO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Salarius Pharma|Rasio rega marang prakiraan pendapatan Purple Biotech|Multiplikator Forward P/S AON|Rasio rega marang prakiraan pendapatan BeiGene (BGNE)|ELEV: Rega mangsa ngarep marang pendapatan|iCAD - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake IKNA (Ikena Oncology Inc.)|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|NAYA Biosciences Inc (NAYA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
